Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP961716priorityCriticalpatent/ECSP961716A/en
Publication of ECSP961716ApublicationCriticalpatent/ECSP961716A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
El invento se refiere al suministro de un método para tratar una condición asociada con la modulación del receptor muscarínico usando una formulación transdérmica de 3-[3-(hexiltio)-1,2,5-tiadiazol-4-il]-1,2,5,6-tetrahidro-1-metilpiridina. La invención suministra formulaciones deseadas transdérmicas de parche de 3-[3-(hexiltio)-1,2,5-tiadiazol-4-il]-1,2,5,6-tetrahidro-1-metilpiridina.The invention relates to the provision of a method of treating a condition associated with modulation of the muscarinic receptor using a transdermal formulation of 3- [3- (hexylthio) -1,2,5-thiadiazol-4-yl] -1,2 , 5,6-tetrahydro-1-methylpyridine. The invention provides desired transdermal patch formulations of 3- [3- (hexylthio) -1,2,5-thiadiazol-4-yl] -1,2,5,6-tetrahydro-1-methylpyridine.